- Home
- BXP vs QGEN Comparison
BXP vs QGEN Comparison
Compare BXP & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | QGEN |
|---|---|---|
| Founded | 1970 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.0B |
| IPO Year | 2000 | 1998 |
Fundamental Metrics
Financial Performance| Metric | BXP | QGEN |
|---|---|---|
| Price | $65.72 | $50.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 12 |
| Target Price | ★ $73.60 | $49.02 |
| AVG Volume (30 Days) | 1.4M | ★ 5.2M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | 4.47% | ★ 5.48% |
| EPS Growth | ★ 1833.33 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,482,279,000.00 | N/A |
| Revenue This Year | $14.11 | $2.18 |
| Revenue Next Year | $2.36 | $5.03 |
| P/E Ratio | $58.59 | ★ $24.01 |
| Revenue Growth | ★ 2.19 | N/A |
| 52 Week Low | $49.93 | $32.53 |
| 52 Week High | $74.94 | $57.82 |
Technical Indicators
Market Signals| Indicator | BXP | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 72.47 |
| Support Level | $57.74 | $49.37 |
| Resistance Level | $67.10 | $50.82 |
| Average True Range (ATR) | 1.53 | 0.91 |
| MACD | 0.57 | 0.09 |
| Stochastic Oscillator | 73.31 | 91.58 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP owns 164 properties consisting of approximately 51.1 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).